Our Team
Jonathan Ward MBA
Co-Founder | Preclinical Strategy & Toxicology Services
Jonathan Ward brings over 20 years of experience in preclinical R&D, toxicology testing, and CRO operations, supporting drug development programs from early screening through IND-enabling studies. He previously served as COO of a preclinical CRO and held senior scientific leadership roles in industry, overseeing regulated safety pharmacology and toxicology study delivery. At Genome Biologics, Jonathan leads client partnerships and execution of cardiac safety screening service packages using TrueCardium® human organoids.
Jaya Krishnan PhD
Co-Founder | Cardiovascular Disease Modeling & Translational Science
Prof. Jaya Krishnan is a cardiovascular disease researcher with more than 20 years of expertise in human-relevant preclinical models, cardiac pathophysiology, and translational drug discovery. Trained at Imperial College London and ETH Zurich, he has led major research programs in cardiovascular and cardiometabolic disease. At Genome Biologics, he oversees scientific strategy and development of advanced TrueCardium® disease models for efficacy testing, mechanism-of-action studies, and NAM-aligned translational evaluation.
Ting Yuan PhD
Head of Research & Drug Discovery | Screening & Multi-Omics Analytics
Dr. Ting Yuan has over a decade of experience in preclinical disease modeling, metabolic research, and drug discovery screening. She has led multiple translational research projects at Goethe University Frankfurt and published extensively in high-impact scientific journals. At Genome Biologics, she directs TrueCardium® screening workflows, mechanistic profiling, and integrated multi-omics analytics, delivering high-resolution datasets for cardiotoxicity assessment and therapeutic target validation.
Pham Minh Duc MSc
Head of Disease Modeling & Translational Screening | Cardiac Organoid Biology & Screening
Dr. Pham Minh Duc is a cardiovascular researcher with expertise in human cardiac organoid disease models and translational drug discovery applications. As Head of Disease Modeling & Translational Screening at Genome Biologics, he leads the development and execution of TrueCardium®-based efficacy and mechanistic studies, supporting pharmaceutical partners in cardiac safety assessment, target validation, and human-relevant therapeutic testing.
Scientific & Clinical Advisory Board
Genome Biologics is supported by an international advisory board of leaders in drug development, clinical translation, cardiometabolic disease, and human-relevant preclinical modeling. Their expertise strengthens the scientific rigor, clinical relevance, and strategic direction of TrueCardium® cardiac organoid services.
Alex Matter MD
CEO, AtumRa Therapeutics | Former Global Oncology Leader (Novartis, Roche)
Expertise: Drug development • Clinical translation • Industry strategy
Dr. Alex Matter is a globally recognized physician-scientist who has led multiple breakthrough therapeutic programs across academia and pharma. He advises Genome Biologics on translational development strategy and the integration of TrueCardium® organoid data into decision-making pipelines for advanced therapeutics.
Jean-Paul Deslypere MD PhD
Director (Asia Pacific), ICON Clinical Research
Expertise: Clinical trials • Endocrinology • Cardiometabolic disease
Dr. Deslypere brings decades of experience in clinical endocrinology and global clinical trial execution. He supports Genome Biologics in aligning cardiac disease models with clinical endpoints and partner needs across cardiometabolic drug development.
Tony Vidal-Puig MBA MD PhD
Professor of Metabolism, University of Cambridge
Expertise: Metabolic disease • HFpEF biology • Translational phenotyping
Prof. Vidal-Puig is a leading authority in cardiometabolic disease mechanisms and systemic metabolism. He advises Genome Biologics on disease-model innovation, particularly in diabetic cardiomyopathy and HFpEF-relevant TrueCardium® platforms.
Jonathan Sleeman PhD
Professor of Microvascular Pathobiology, University of Heidelberg
Expertise: Vascular biology • Inflammation • Disease remodeling
Prof. Sleeman is an expert in microvascular dysfunction and inflammatory remodeling in complex disease. He supports Genome Biologics in advancing vascularised cardiac organoid models for inflammation-driven cardiovascular pathology and mechanistic discovery.
Our advisors ensure that TrueCardium® screening and disease modeling services remain clinically grounded, regulatory-relevant, and aligned with the needs of pharmaceutical development teams.